Neoplasm
Conditions
Brief summary
Therapeutic education is an effective way to support the prescription of oral chemotherapy in oncology. It aims to increase adherence to treatment, to better control the side effects and reduce unplanned readmissions. The three major oncology institutions in the Rhône-Alpes region (Hospices Civils de Lyon, the Centre Léon Bérard Cancer Institute and Lucien Neuwirth) decided to collaborate on a project to implement an adapted Therapeutic Education Program context of each of these institutions. The objective of this study is to evaluate the implementation of the intervention in the 3 participating centers, over 1 year: 1. Assess the achievement of the target population 2. Evaluate the adaptation of intervention in context 3. Evaluate the effectiveness of the intervention (impact): effectiveness in real life, identification of interactions with the environment linked to the center, identification of unintended effects of the intervention. 4. Assessing the sustainability of the intervention
Interventions
BEHAVIORALtherapeutic education program
Sponsors
Hospices Civils de Lyon
Centre Leon Berard
Institut de Cancérologie de la Loire
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient care in medical oncology services of the Cancer Institute of Lucien Neuwirth, the Lyon-Sud hospital and the Centre Léon Bérard: * Age over 18 years * Introducing an active cancer (local extension, locoregional or metastatic) * Oral chemotherapy as monotherapy or in combination with other treatments, initiated or in progress
Exclusion criteria
* Refusal to participate, protected adult patient under guardianship. * Patient disability to understand the course of the study, the Therapeutic education program, or failure to follow the educational sessions. * Patient with documented history of cognitive or psychiatric disorders. * Patient on adjuvant therapy or hormone therapy for prostate cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage of affected population | 3 months | — |
| Level of acquisition of knowledge | 3 months | Questionnaire composed of numerous questions dealing with patient's knowledge about his/her disease, treatment and treatment's side effects . Answers are quoted in Yes/No and a global scoring is made with all answers. Final measure is a percentage of good answers. |
| Anxiety and Depression | 3 months | measured with the Hospital Anxiety Depression Scale (Zigmond & Snaith, 1983 ), wich gives separated results about the level of anxiety and of depression according to the level of scoring to a set of 14 questions. Questions are rated from 0-3, and the anxiety and depression subscale scores range from 0-21. The cutoff for each subscale is eight. |
| Quality of Life Questionnaire | 3 months | — |
| Morisky Measurement Adherence Scale | 3 months | — |
Countries
France
Contacts
Primary ContactAurélie BOURMAUD, MD
Outcome results
None listed